Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 20, pp. 1919-1929
Open Access | Times Cited: 3826

Showing 1-25 of 3826 citing articles:

The biology and management of non-small cell lung cancer
Roy S. Herbst, Daniel Morgensztern, Chris Boshoff
Nature (2018) Vol. 553, Iss. 7689, pp. 446-454
Closed Access | Times Cited: 3791
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 651-668
Open Access | Times Cited: 3206
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 24, pp. 2342-2350
Open Access | Times Cited: 2474
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, et al.
Annals of Oncology (2018) Vol. 30, Iss. 1, pp. 44-56
Open Access | Times Cited: 2258
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
Daniel Wang, Joe-Élie Salem, Justine V. Cohen, et al.
JAMA Oncology (2018) Vol. 4, Iss. 12, pp. 1721-1721
Open Access | Times Cited: 2049
Regulation and Function of the PD-L1 Checkpoint
Chong Sun, Riccardo Mezzadra, Ton N. Schumacher
Immunity (2018) Vol. 48, Iss. 3, pp. 434-452
Open Access | Times Cited: 1819
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 21, pp. 1976-1986
Open Access | Times Cited: 1804
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma, Rafael Santana-Dávila, Julian R. Molina
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 8, pp. 1623-1640
Closed Access | Times Cited: 1696
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luís Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
The Lancet (2019) Vol. 394, Iss. 10212, pp. 1929-1939
Closed Access | Times Cited: 1696
Lung cancer
Alesha Thai, Benjamin Solomon, Lecia V. Sequist, et al.
The Lancet (2021) Vol. 398, Iss. 10299, pp. 535-554
Closed Access | Times Cited: 1654
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1606
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 325-340
Open Access | Times Cited: 1539
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alex Chehrazi‐Raffle, Srikanth Reddi, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 1148
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1344-1357
Closed Access | Times Cited: 1090
Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano, Marta Joana Costa Jordão, Johanna A. Joyce
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 933-959
Open Access | Times Cited: 1071
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon, Coleman E. Johnson, Corey J. Williams
International Immunopharmacology (2018) Vol. 62, pp. 29-39
Closed Access | Times Cited: 1053
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1012
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 9, pp. 1180-1191
Closed Access | Times Cited: 1002
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 725-741
Closed Access | Times Cited: 993
The lung microenvironment: an important regulator of tumour growth and metastasis
Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, et al.
Nature reviews. Cancer (2018) Vol. 19, Iss. 1, pp. 9-31
Open Access | Times Cited: 904
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David R. Spigel, C. Faivre‐Finn, Jhanelle E. Gray, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 12, pp. 1301-1311
Open Access | Times Cited: 847
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 822
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 811
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone, Salvatore Salomone, Massimo Libra
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 785
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fučíková, Oliver Kepp, Lenka Kašíková, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 747
Page 1 - Next Page

Scroll to top